Stifel lowered the firm’s price target on Aemetis to $6.50 from $8 and keeps a Buy rating on the shares. The company recently released its updated five-year plan, which included guidance below the firm’s expectations, the analyst tells investors. Despite the guidance miss, the firm believes investors will remain focused on the company’s progress on addressing the balance sheet and important regulatory developments.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMTX:
- Aemetis Releases Updated Five Year Plan Information
- Aemetis Announces Updated Five Year Plan Projecting Growth to $1.95 Billion of Revenue and $645 Million of Adjusted EBITDA in 2028
- Aemetis Subsidiaries Extend Repayment on $117M Notes
- Aemetis Amends Biogas Project Financing Terms
- Aemetis completes construction funding from $25M USDA loan
